AC0078 – TRK Inhibitor

AC0078 is a novel small molecule inhibitor of tropomyosin receptor kinases (TRK). This family of signaling proteins is implicated in oncogenic rearrangements that result activated fusion kinases found in a many adult and pediatric cancers. AC0078 has shown potent and selective activity against wild-type and mutant TRKs in kinase enzyme and cell-based assays.

AC0078 is currently being studied in multiple disease models to establish its efficacy, pharmacokinetic and safety parameters ahead of anticipated clinical trials.

AC0078 is currently in preclinical studies for in vivo efficacy in multiple disease models.